

# Remodeling oncolytic virotherapy

Orfeas Gkourlias & Dennis Wiersma

2022-06-17

## Abstract

some text

# Contents

<b>1</b>	<b>Introduction</b>	<b>4</b>
<b>2</b>	<b>Methods</b>	<b>5</b>
2.1	Variables . . . . .	5
2.2	Formulas . . . . .	5
2.2.1	Normal susceptible cell count . . . . .	5
2.2.2	Tumour susceptible cell count . . . . .	5
2.2.3	Normal infected cell count . . . . .	5
2.2.4	Tumour infected cell count . . . . .	5
2.2.5	Virion count . . . . .	6
<b>3</b>	<b>Results</b>	<b>7</b>
<b>4</b>	<b>Discussion</b>	<b>8</b>
<b>5</b>	<b>Conclusion</b>	<b>9</b>
<b>6</b>	<b>Bibliography</b>	<b>10</b>

## List of Figures

## List of Tables

1	All variables and their respective explanations . . . . .	5
---	---	---

# 1 Introduction

Viruses and cancer are both considered to be very destructive and harmful. But what if one of these could be used to combat the other? Viruses infect cells. These cells do not have to be healthy ones. By introduction of specific viruses into tumor affected tissue, the tumor may be repressed and eventually entirely eliminated. The field known as oncolytic virotherapy is still developing. There's still many uncertainties, but also possibilities. This paper aims to reproduce and possibly revise another paper published in the journal of theoretical biology. The paper demonstrated extensive modelling relevant to exploring the effects of varying amounts of normal and tumor cells.

Oncolytic virotherapy has a lot of potential. With that comes many things to consider. Before diving deeper and challenging some of these considerations in more mathematical detail, let's ask some general important questions. What is the desired balance of infection? Viruses used in these treatments don't exclusively infect tumor cells. This could either be beneficial or a hindrance. At which amount of infection does one group start to suffer? And what are the ideal ratios when it comes to tumor to normal cell infection? As the amount of tumor cells declines, it becomes harder for the virus in the system to find and infect tumor cells before the immune system eliminates the virus completely. This could result in stray tumor cells being left behind, only delaying the growth until it propagates significantly again. This is also only addressing the use of viruses which lyses the tumor cells. Some viral infections may cause the cells to be more susceptible to other forms of treatment, such as chemotherapy. This brings in a whole other amount of variables to consider.

In any case, the immune response is of great importance. The immune response may vary from person to person and tissue to tissue. Whether the person had been exposed to a virus before, or the immune system engages an unknown pathogen mediates different responses too. It's important to be aware of those factors in treatment. Time is of the essence in all instances of virotherapy. It usually takes 5 to 7 days for the immune response to completely halt production rate of the virus. As mentioned earlier, it's important that the treatment, in the case of the lysis approach, destroys all of the tumor cells. Having to accomplish this in the time frame of only 5 to 7 days is quite a feat. This swift approach is referred to as one shot virotherapy. This is why it's so important for the initial values to be right, further solidifying the significance of researching and being absolutely certain about the relevant mathematical models, due to there only being one shot at the initial treatment with a specific virus.

## 2 Methods

[1]

### 2.1 Variables

Variable	Explanation	Unit
$t$	Time	hr <sup>-1</sup>
$H$	Normal (Healthy) cell type	-
$C$	Tumour (Cancerous) cell type	-
$H_S$	Normal cell that is susceptible	-
$H_I$	Normal cell that is infected	-
$C_S$	Tumour cell that is susceptible	-
$C_I$	Tumour cell that is infected	-
$K_H$	Carrying capacity of normal cells	cells
$K_C$	Carrying capacity of tumour cells	cells
$\beta_H$	Infection rate of normal cells	viruses cell <sup>-1</sup> hr <sup>-1</sup>
$\beta_C$	Infection rate of tumour cells	viruses cell <sup>-1</sup> hr <sup>-1</sup>
$\lambda_H$	Lysing rate of normal cells	cell <sup>-1</sup> hr <sup>-1</sup>
$\lambda_C$	Lysing rate of tumour cells	cell <sup>-1</sup> hr <sup>-1</sup>
$b_H$	Burst size of normal cells	-
$b_C$	Burst size of tumour cells	-
$r_H$	Per-capita growth rate of normal cells	hr <sup>-1</sup>
$r_C$	Per-capita growth rate of tumour cells	hr <sup>-1</sup>
$\omega$	Rate of neutralisation by innate immune response	virus <sup>-1</sup> hr <sup>-1</sup>
$v$	Virions	-

Table 1: All variables and their respective explanations

Reference to table one: 1

### 2.2 Formulas

#### 2.2.1 Normal susceptible cell count

$$\frac{dH_S}{dt} = r_H H_S \left(1 - \frac{(H_S + H_I)}{K_H}\right) - H_S \beta_H v \quad (1)$$

#### 2.2.2 Tumour susceptible cell count

$$\frac{dC_S}{dt} = r_C C_S \left(1 - \frac{(C_S + C_I)}{K_C}\right) - C_S \beta_C v \quad (2)$$

#### 2.2.3 Normal infected cell count

$$\frac{dH_I}{dt} = \beta_H H_S v - \lambda_H H_I \quad (3)$$

#### 2.2.4 Tumour infected cell count

$$\frac{dC_I}{dt} = \beta_C C_S v - \lambda_C C_I \quad (4)$$

### 2.2.5 Virion count

$$\frac{dv}{dt} = b_C \lambda_C C_I + b_H b_C \lambda_H H_I - \beta_H H_S v - \beta_C C_S - \omega v \quad (5)$$

Referentie naar eq1: (1)

### 3 Results

## 4 Discussion



## 5 Conclusion

## 6 Bibliography

### References

- [1] Kenichi W. Okamoto, Priyanga Amarasekare, and Ian T.D. Petty. “Modeling oncolytic virotherapy: Is complete tumor-tropism too much of a good thing?” In: *Journal of Theoretical Biology* 358 (2014), pp. 166–178. ISSN: 0022-5193. DOI: <https://doi.org/10.1016/j.jtbi.2014.04.030>. URL: <https://www.sciencedirect.com/science/article/pii/S0022519314002604>.